{"id":"W3047494536","doi":"10.1136/jitc-2020-000883","title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Foundation; Canada Research Chairs; AstraZeneca; Celgene; Canadian Institutes of Health Research; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Regimen; Hypomethylating agent; Internal medicine; Adverse effect; Breast cancer; Oncology; Gastroenterology; Immunology; DNA methylation; Cancer; Immunotherapy; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001829709,0.001271159,0.002804904,0.0004581024,0.0005222472,0.000958594,0.001052049,0.001182602,0.002833351],"category_scores_gemma":[0.0009970668,0.0007632559,0.0008899175,0.0004126885,0.001241388,0.0012646,0.0003450263,0.002848865,0.0006160861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008408873,"about_ca_system_score_gemma":0.00147609,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006860949,"about_ca_topic_score_gemma":0.001901886,"domain_scores_codex":[0.9993733,0.0003054281,0.0000314288,0.0001151302,0.00006566198,0.0001091346],"domain_scores_gemma":[0.9991197,0.0001703106,0.0001659724,0.0001201686,0.00005282402,0.0003708556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7662504,0.1369083,0.003022279,0.0003970815,0.0008463057,0.00009393578,0.0001920906,0.001354548,0.04059989,0.0001408772,0.0008916272,0.04930263],"study_design_scores_gemma":[0.3869754,0.6023699,0.004563338,0.00001217442,0.000266272,0.0001033946,0.00005117758,0.0007311639,0.00383792,0.0001115251,0.0009566571,0.00002111099],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997245,0.0006011061,0.0003269796,0.0001092288,0.00007357002,0.001054018,0.0002164819,0.00003120881,0.0003425028],"genre_scores_gemma":[0.9940236,0.0006824631,0.001355245,0.0002679505,0.0001780121,0.001610676,0.0004616801,0.00001849171,0.001401932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002833351,"threshold_uncertainty_score":0.009676576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0510288598174325,"score_gpt":0.4253666546034957,"score_spread":0.3743377947860632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}